Edition:
United States

Dignitana AB (DIGN.ST)

DIGN.ST on Stockholm Stock Exchange

19.80SEK
29 Jul 2016
Change (% chg)

0.60kr (+3.12%)
Prev Close
19.20kr
Open
19.20kr
Day's High
19.80kr
Day's Low
19.10kr
Volume
22,348
Avg. Vol
25,746
52-wk High
24.27kr
52-wk Low
11.00kr

DIGN.ST

Chart for DIGN.ST

About

Dignitana AB is a Sweden-based medical technology company. It develops, manufactures and markets a medical device primarily used for scalp cooling in order to eliminate or reduce chemotherapy induced hair loss. The Company focuses on the product DigniCap, which counteracts hair loss during chemotherapy. The product is a cold... (more)
No analyst recommendations are available for DIGN.ST.

Overall

Beta: -0.11
Market Cap(Mil.): kr401.43
Shares Outstanding(Mil.): 20.27
Dividend: --
Yield (%): --

Financials

  DIGN.ST Industry Sector
P/E (TTM): -- 41.77 39.28
EPS (TTM): -1.21 -- --
ROI: -64.37 11.59 14.40
ROE: -64.37 13.55 15.47

BRIEF-Dignitana: rights issue oversubscribed

* Rights issue of 19.4 million Swedish crowns ($2.3 million)oversubscribed

Jun 17 2016

BRIEF-Dignitana Q1 pre-tax loss widens to SEK 5.9 million

* Q1 net sales 1.1 million Swedish crowns ($132,381.79) versus 3.0 million crowns year ago

May 25 2016

BRIEF-Dignitana: Agreements with 21 US hospitals since FDA approval in December 2015

* Has signed agreements with 21 US hospitals since FDA approval in December 2015 Source text for Eikon:

May 24 2016

BRIEF-Dignitana carries out private placement and rights issue of total SEK 52.5 million

* Carries out private placement and rights issue of total 52.5 million Swedish crowns ($6.38 million)

May 16 2016

BRIEF-Dignitana brings DigniCap to three more cities in the U.S.

* Dignitana brings FDA-cleared DigniCap system to three more cities in the U.S.

Apr 28 2016

BRIEF-Dignitana scalp cooling system comes to three more U.S. cancer treatment centers

* Says DigniCap scalp cooling system, which was recently cleared by the FDA to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, is now also available at cancer treatment centers in Tampa and Palm Beach, Florida and Battle Creek, Michigan Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Apr 18 2016

BRIEF-Dignitana Q4 operating loss 5.3 million crowns

* Q4 operating loss 5.3 million crowns ($622,094.93) Source text for Eikon: Further company coverage: ($1 = 8.5196 Swedish crowns) (Gdynia Newsroom)

Feb 24 2016

BRIEF-Dignitana receives orders from hospitals in Texas and California 

* Agreements mean that the company received a total of six orders in the US

Feb 15 2016

Earnings vs. Estimates

No consensus analysis data available.

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : Sadif Analytics Prime
$10.00
Provider : GlobalData
$300.00
Provider : Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.